PL2510011T3 - Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania - Google Patents

Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania

Info

Publication number
PL2510011T3
PL2510011T3 PL10813116T PL10813116T PL2510011T3 PL 2510011 T3 PL2510011 T3 PL 2510011T3 PL 10813116 T PL10813116 T PL 10813116T PL 10813116 T PL10813116 T PL 10813116T PL 2510011 T3 PL2510011 T3 PL 2510011T3
Authority
PL
Poland
Prior art keywords
bind
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
PL10813116T
Other languages
English (en)
Polish (pl)
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2510011(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of PL2510011T3 publication Critical patent/PL2510011T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10813116T 2009-12-09 2010-12-08 Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania PL2510011T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof
EP10813116.0A EP2510011B2 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof

Publications (1)

Publication Number Publication Date
PL2510011T3 true PL2510011T3 (pl) 2015-02-27

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10813116T PL2510011T3 (pl) 2009-12-09 2010-12-08 Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania

Country Status (18)

Country Link
US (2) US8822652B2 (enExample)
EP (1) EP2510011B2 (enExample)
JP (2) JP2013513380A (enExample)
CN (2) CN104926942B (enExample)
BR (1) BR112012013975B8 (enExample)
CA (1) CA2783740C (enExample)
DK (1) DK2510011T3 (enExample)
EA (1) EA024629B1 (enExample)
ES (1) ES2523472T3 (enExample)
HR (1) HRP20141170T1 (enExample)
IN (1) IN2012DN04908A (enExample)
MX (1) MX2012006443A (enExample)
PL (1) PL2510011T3 (enExample)
PT (1) PT2510011E (enExample)
RS (1) RS53667B1 (enExample)
SI (1) SI2510011T1 (enExample)
SM (1) SMT201400184B (enExample)
WO (1) WO2011070443A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
HRP20141170T1 (hr) 2009-12-09 2015-01-30 Institut National de la Santé et de la Recherche Médicale Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
BR112014005573A2 (pt) * 2011-09-13 2014-11-11 Deutsches Krebsforsch Anticorpo monoclonal b7-h6 terapeuticamente ativo contra polipeptídeo b7-h6
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
WO2017181001A1 (en) * 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments
US11191771B2 (en) * 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
EP3710481A4 (en) * 2017-11-16 2021-08-18 Antigenesis LLC LYSOSOME-INDUCED IMMUNOGENIC CELL DEATH SYSTEMS AND PROCEDURES
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
AU2021207165A1 (en) * 2020-01-17 2022-07-21 Beigene, Ltd. Anti-NKp30 antibodies and methods of use
AU2022246048A1 (en) 2021-03-26 2023-08-31 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
KR20240019297A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
KR20240003756A (ko) * 2022-06-29 2024-01-09 고려대학교 산학협력단 NKp30 결합력이 향상된 B7-H6 변이체
JP2025537792A (ja) * 2022-11-16 2025-11-20 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 疾患治療での使用のためのｔ細胞－ｎｋ細胞相互作用阻害剤
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
FI102355B (fi) 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
JP2002513402A (ja) 1997-02-25 2002-05-08 アリゾナ ボード オブ リーゼンツ 細胞増殖抑制性の鎖状および環状デプシペプチドであるドラスタチン１６、ドラスタチン１７およびドラスタチン１８の単離と構造決定
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2001051514A1 (en) * 2000-01-07 2001-07-19 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
WO2006124668A1 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Methods of using pnkp30, a member of the b7 family, to modulate the immune system
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
EA201000343A1 (ru) * 2007-10-04 2011-10-31 Займодженетикс, Инк. ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
HRP20141170T1 (hr) 2009-12-09 2015-01-30 Institut National de la Santé et de la Recherche Médicale Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe

Also Published As

Publication number Publication date
CA2783740A1 (en) 2011-06-16
US9663577B2 (en) 2017-05-30
EA201270654A1 (ru) 2013-02-28
EP2510011B2 (en) 2021-03-31
SMT201400184B (it) 2015-01-15
IN2012DN04908A (enExample) 2015-09-25
JP2017031147A (ja) 2017-02-09
US20130004432A1 (en) 2013-01-03
WO2011070443A1 (en) 2011-06-16
ES2523472T3 (es) 2014-11-26
JP6212181B2 (ja) 2017-10-11
CN104926942B (zh) 2018-09-14
BR112012013975B8 (pt) 2021-05-25
CN104926942A (zh) 2015-09-23
PT2510011E (pt) 2014-12-12
US20150056214A1 (en) 2015-02-26
RS53667B1 (sr) 2015-04-30
CN102741290A (zh) 2012-10-17
MX2012006443A (es) 2012-06-28
HRP20141170T1 (hr) 2015-01-30
CN102741290B (zh) 2015-04-22
US8822652B2 (en) 2014-09-02
SI2510011T1 (sl) 2014-12-31
EA024629B1 (ru) 2016-10-31
JP2013513380A (ja) 2013-04-22
BR112012013975A2 (pt) 2017-01-10
BR112012013975B1 (pt) 2021-01-12
DK2510011T3 (en) 2014-12-01
CA2783740C (en) 2020-03-10
EP2510011B1 (en) 2014-09-17
EP2510011A1 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
PT2510011E (pt) Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
IL215649A (en) Monoclonal antibodies against TNF-α and their use
EP2501724A4 (en) MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF
SG10201601279SA (en) Monoclonal Antibody STRO-4
EP2331579A4 (en) MONOCLONAL ANTIBODIES
PT2374883T (pt) Anticorpo anti-cd4
EP2533810A4 (en) CD20 ANTIBODIES AND ITS USE
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
AP2011005859A0 (en) Humanized antibodies that bind to CD19 and their uses.
IL218724A0 (en) Endoglin antibodies
ZA201202227B (en) Monoclonal antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
ZA201108310B (en) Blocking anti-dkk-1 antibodies and their uses
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
IL206898A0 (en) HUMANIZED ANTI-HUMAN a9-INTEGRIN ANTIBODY AND USES THEREOF
GB0903151D0 (en) Antibody uses and methods
IL214755A (en) A monoclonal antibody against rhd and various aspects associated with it
GB0906115D0 (en) Antibody and uses thereof
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF